Open AccessTYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer
Author(s) -
Anastasios Ntavatzikos,
Aris Spathis,
Paul Patapis,
Nikolaos Machairas,
Georgia Vourli,
George Peros,
Iordanis N. Papadopoulos,
Ioannis G. Panayiotides,
Anna Koumarianou
Publication year - 2019
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v11.i7.551
Subject(s) - kras , medicine , colorectal cancer , oncology , hazard ratio , thymidylate synthase , oxaliplatin , chemotherapy , proportional hazards model , panitumumab , cancer , confidence interval , fluorouracil
Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase ( TYMS ) gene polymorphisms, KRAS and BRAF could be included in the molecular profile under consideration.